Bayer's Pipeline Delivers Substance as a Supreme Court Verdict Holds the Key to Re-rating

Bayer shares rise 5% as stroke drug Asundexian nears European approval, but a US Supreme Court decision on glyphosate liability looms with billions at stake.

Bayer shares are being pulled in two opposing directions at once. On one side, the pharmaceutical pipeline is gaining tangible momentum with a new stroke-prevention drug nearing regulatory approval. On the other, a single Supreme Court ruling due this month could wipe away billions in legal liabilities — or let them fester. The stock jumped 4.6% to €37.51 on Thursday, marking the highest level of the month, and closed the week at €37.76, a gain of roughly 5%. It now sits just above its 200-day moving average of €36.17, but remains 24% below the 52-week high of €49.93.

Asundexian edges closer to market

The most critical near-term catalyst on the pharma side is Asundexian. The European Medicines Agency has accepted the marketing application for the Factor XIa inhibitor — the first such filing in Europe, according to Bayer. The submission is complete, and central review is underway. The Phase III OCEANIC-STROKE trial demonstrated a 26% reduction in the risk of recurrent stroke compared with placebo. Applications have also been filed in the United States and China, where regulators granted Priority Review, signalling high medical need.

The timing is crucial. Xarelto, Bayer’s blockbuster anticoagulant, lost patent protection last year, and its revenue collapsed by a third to $2.6 billion in 2025. Asundexian is the designated successor. Bayer is ahead of Bristol Myers Squibb and Johnson & Johnson, which are developing the rival drug Milvexian. Meanwhile, other pipeline assets are delivering: Nubeqa and Kerendia continue to show strong growth, and the company secured market approvals for Beyonttra and Lynkuet in 2025.

China as an innovation hub, not just a sales market

Bayer Consumer Health has quietly opened its second China Center of Innovation and Partnership, this time in Shandong province. Innovations developed there are destined for markets in Australia and the Asia-Pacific region. The group already generates around €3.5 billion in annual revenue from China and is increasingly using the country as a springboard for global pipeline development.

Operational progress, but legal costs bite

First-quarter results for 2026 highlight the internal tension. Group revenue rose 4.1% on a currency- and portfolio-adjusted basis to €13.4 billion, while EBITDA before special items increased by 9.0%. Then came the legal drag: net cash outflows of €2.0 billion for PCB and glyphosate lawsuits in the quarter alone. Net financial debt stood at €32.5 billion at the end of March. Operational momentum exists, but it is being systematically consumed by litigation costs.

That has prompted some shareholders to push for a structural review. A possible spin-off of the Consumer Health division has been floated as one option to unlock value.

Supreme Court decision: binary risk with billions at stake

The legal calendar is dominated by the case “Durnell” before the US Supreme Court. At issue is whether federal law — specifically the EPA's determination that glyphosate is safe — overrides state-law claims about warning labels. A ruling in Bayer’s favour could render the vast majority of the roughly 65,000 outstanding glyphosate lawsuits invalid. A negative verdict would keep the litigation rolling. The decision is expected later this month.

An additional tailwind came from Brussels: foods produced using modern genetic engineering techniques will no longer require special labelling in the EU. That structurally strengthens Bayer’s Crop Science division. UBS analyst Matthew Weston holds a price target of €52 on the stock, nearly 40% above current levels.

Leadership continuity amid uncertainty

Bayer’s supervisory board has extended CEO Bill Anderson’s contract through March 2029, signalling a commitment to strategic continuity. But until the Supreme Court rules, the share price is likely to remain hostage to legal headlines rather than operational achievements. The pipeline story is real — the full re-rating, however, will have to travel through the courtroom.